[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360807-105":59,"doc-detail-360807-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","risk-prediction-for-lung-cancer-screening-a-systematic-review-and-meta-regression","Risk prediction for lung cancer screening: a systematic review and meta-regression","","Lung cancer remains the deadliest malignancy and is frequently diagnosed at advanced stages, despite evidence that low-dose computed tomography (LDCT) screening can reduce mortality in high-risk groups. Eligibility criteria in European and US guidelines have expanded in recent years, prompting an updated systematic review of risk-based models. The review searches studies from January 2020 to January 2026, extracts model design and performance, and conducts exploratory meta-regression of AUCs to evaluate factors linked to predictive performance.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/risk-prediction-for-lung-cancer-screening-a-systematic-review-and-meta-regression/360807/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/risk-prediction-for-lung-cancer-screening-a-systematic-review-and-meta-regression/360807.png","ImageObject",300,407,{"name":92,"@type":93},"Blitz","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the purpose of this systematic review?","Question",{"text":112,"@type":113},"To update the evidence on risk-based prediction models used to identify candidates for LDCT screening and for post-screening nodule classification.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the included risk models selected and analyzed?",{"text":117,"@type":113},"Studies proposing new lung cancer risk models for screening were systematically searched (Embase and Medline, January 2020–January 2026), with models separated by pre-screening and post-screening risk stratification and then analyzed using extracted performance metrics and exploratory meta-regression of AUCs.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the review find about model performance and validation?",{"text":121,"@type":113},"A total of 91 models were included; discrimination ranged from moderate to excellent, but calibration was inconsistently reported and fewer than half underwent external validation, limiting readiness for clinical adoption.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},360807,1790293720,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":24,"preview_urls":146},24464137899374,"https://us-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","EUROPEAN RESPIRATORY REVIEW REVIEW  \nR. REZAEIANZADEH ET AL.  \nRisk prediction for lung cancer screening: a systematic review and meta-regression  \nRamin Rezaeianzadeh 1, Crystal Leung 1, Soo Jeong Kim1, Kayly Choy1, Kate M. Johnson 2,3, Miranda Kirby4, Stephen Lam 3, Benjamin M. Smith5 and Mohsen Sadatsafavi 1  \n1 Respiratory Evaluation Sciences Program, Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada. 2Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada. 3 Division of Respiratory Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada. 4 Department of Physics, Toronto Metropolitan University, Toronto, ON, Canada. 5 Department of Medicine, McGill University, Montreal, QC, Canada.  \nCorresponding author: Mohsen Sadatsafavi ( [Mohsen.Sadatsafavi@ubc.ca](Mohsen.Sadatsafavi@ubc.ca))  \nShareable abstract (@ERSpublications)  \n91 new lung cancer risk models have been identified since 2020 . Despite strong discrimination, limited validation and calibration could hinder adoption. Focus should shift to improving existing models, evaluation, cost-effectiveness and real-world impact. [https://bit.ly/4efpbvh](https://bit.ly/4efpbvh)  \n[Cite this article as:](Cite this article as: Rezaeianzadeh R)[ Rezaeianzadeh R](Cite this article as: Rezaeianzadeh R), [Leung C](Leung C), [Kim SJ](Kim SJ), et al. Risk prediction for lung cancer screening: a systematic review and meta-regression. Eur Respir Rev 2026; 35: 250295 [DOI: 10.1183/ 16000617.0295-2025] .  \nCopyright ©The authors 2026  \nThis version is distributed under the terms of the Creative Commons Attribution NonCommercial Licence 4 .0. For commercial reproduction rights and permissions contact [permissions@ersnet.org](permissions@ersnet.org)  \nReceived: 13 Nov 2025  \nAccepted: 19 April 2026  \nAbstract  \nBackground Lung cancer (LC) remains the deadliest cancer, often diagnosed at advanced stages. Screening reduces mortality in high-risk individuals. Eligibility criteria in European and US screening guidelines have recently expanded. Therefore, we conducted an updated systematic review of risk-based models for identifying candidates for low-dose computed tomography screening and post-screening nodule classification.  \nMethods We systematically searched Embase and Medline (January 2020–January 2026), identifying studies proposing new risk models in the context of LC screening. We separated models by pre- and postscreening risk stratification. Data extraction included study design, population, model type, risk horizon and model performance metrics. We performed an exploratory meta-regression of areas under the curve (AUCs) to assess whether sample size, model type, validation type and inclusion of biomarkers were associated with performance.  \nResults Of 2462 records, 91 were included. 56 models were for screening selection (30 included biomarkers) and 35 for post-screening nodule classification. Regression-based models predominated, though machine-learning approaches were increasingly common. Discrimination ranged from moderate (AUC∼0.70) to excellent (>0.90), with biomarker and imaging-enhanced models often outperforming models without. Calibration was inconsistently reported and fewer than half underwent external validation. Conclusion We identified 91 risk prediction models for LC, developed after 2020 . Although many demonstrated promising discrimination across both screening selection and post-screening management, most remain insufficiently mature for clinical adoption, as their performance and practical value outside the original study setting are uncertain. Future work should prioritise external validation, updating and comparative evaluation of existing models, and prospective implementation studies rather than continued development of additional models.  \nIntroduction  \nLun","cbCaimY17i5PPWjC","https://ap.wps.com/l/cbCaimY17i5PPWjC","pdf",877401,42,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction\n## Lung cancer burden and rationale for screening\n## Guideline and programme developments","[{\"question\":\"What is the purpose of this systematic review?\",\"answer\":\"To update the evidence on risk-based prediction models used to identify candidates for LDCT screening and for post-screening nodule classification.\"},{\"question\":\"How were the included risk models selected and analyzed?\",\"answer\":\"Studies proposing new lung cancer risk models for screening were systematically searched (Embase and Medline, January 2020–January 2026), with models separated by pre-screening and post-screening risk stratification and then analyzed using extracted performance metrics and exploratory meta-regression of AUCs.\"},{\"question\":\"What did the review find about model performance and validation?\",\"answer\":\"A total of 91 models were included; discrimination ranged from moderate to excellent, but calibration was inconsistently reported and fewer than half underwent external validation, limiting readiness for clinical adoption.\"}]","Risk prediction for lung cancer screening: a systematic review and meta-regression | PDF",1790141648,106,[147,151,155,159,163],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/eb390ae0e6165ee168eb97084fceb300.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d8a2f087615e779cdcbf152a900f05d4.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/799ec49e75f61f8fe7d53c1f32574186.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c16b42013bfae10fae2f1fe9f750f41f.webp",980,1306,{"page_no":24,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2284fe762042155eebbc153a1da5fc09.webp",979,1305]